Senate grants the FDA a 6.5% raise in funding
increase over the previous year. The Senate Appropriations Committee reported out the agency's spending provision as part of the agriculture appropriations bill.
The measure includes “increases of $50.5 million for pandemic avian influenza preparedness, $8.6 million for medical device and animal drug review, $4.0 million for drug safety, $5.5 million for food safety, $10.0 million for generic drug review, $5.9 million for the Critical Path initiative, and $2.5 million for human tissue safety,” a committee release said.
It noted that the bill does not include language addressing the FDA's authority to require post-marketing studies of drugs, a provision dropped by the House when it passed its version in May.
The bill does, however, include language representing a compromise agreement requiring the FDA to provide advance notification about conflicts of interest waivers granted to outside experts impaneled as “special government employees” on FDA advisory committees, 15 days prior to committee meetings.